Loading…
Anika Therapeutics, Inc. is projected to rise to $23.09 by 2027, a +20% move from its current price of $19.28. ANIK is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $18.67 | $19.27 | $19.90 | -0.03% |
| Aug 4 | $18.42 | $19.27 | $20.16 | -0.05% |
| Aug 5 | $18.22 | $19.26 | $20.36 | -0.08% |
| Aug 6 | $18.06 | $19.26 | $20.53 | -0.11% |
| Aug 7 | $17.92 | $19.25 | $20.68 | -0.14% |
| Aug 8 | $17.80 | $19.25 | $20.82 | -0.16% |
| Aug 9 | $17.68 | $19.24 | $20.95 | -0.19% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $17.68 | $19.24 | $20.95 | -0.19% |
| Week 2 | $17.04 | $19.21 | $21.65 | -0.38% |
| Week 3 | $16.55 | $19.17 | $22.20 | -0.57% |
| Week 4 | $16.15 | $19.13 | $22.67 | -0.76% |
| Week 5 | $15.80 | $19.10 | $23.08 | -0.95% |
| Week 6 | $15.49 | $19.06 | $23.46 | -1.14% |
| Week 7 | $15.20 | $19.02 | $23.81 | -1.32% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Anika Therapeutics, Inc. is a joint preservation company focused on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation.
It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and ophthalmic products; and Anikavisc and Nuvisc high molecular weight HA products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
ANIK is currently priced at $18.07, with a market cap of $241.83M and a market rank of 3458. These fundamentals place the stock among smaller-cap healthcare names with a focused portfolio in joint preservation and OA pain management. The latest price outlook is framed by a year-by-year forecast that mixes gradual near-term stability with meaningful longer-term upside.
The forecast shows a path from 2026 onward with rising averages and sizable potential returns in the back half of the decade and into 2050.
A major floor 35.7% below — a decisive break under it would weaken the trend.
The nearest floor, 26.3% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 17.6% above — clearing it would confirm fresh momentum.
Key ANIK support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ANIK market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $16.74 | Buy | $17.30 | Buy |
| MA 10 | $15.85 | Buy | $16.46 | Buy |
| MA 20 | $15.84 | Buy | $15.91 | Buy |
| MA 50 | $15.16 | Buy | $15.32 | Buy |
| MA 100 | $14.95 | Buy | $14.55 | Buy |
| MA 200 | $12.52 | Buy | $13.64 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 78.65 | Sell |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 324.29 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.34 | Buy |
| ROC (12) | 21.03 | Buy |
| Bollinger %B (20,2) | 1.30 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.20 | Buy |
| Awesome (5,34) | 1.37 | Buy |
| Ultimate (7,14,28) | 85.32 | Sell |
| Momentum (10) | 4.03 | Buy |
| Aroon Osc (25) | 100.00 | Buy |
| Hull MA (9) | 18.02 | Buy |
| ADX (14) | 16.77 | Neutral |
| ATR (14) | 0.48 | Info |
The 30-day technical picture is bullish. RSI14 sits at 70, signaling strong upward momentum. The stock trades above both the SMA50 of $15.07 and the SMA200 of $12.47, suggesting a positive trend. Support is at $14.20 and resistance at $18.07, providing a defined near-term trading band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $9.13 | $19.28 | $24.54 | 0% | Neutral | |
| $18.12 | $23.09 | $31.26 | +20% | Neutral | |
| $21.96 | $28.94 | $40.91 | +50% | Bullish | |
| $25.02 | $33.90 | $49.56 | +76% | Bullish | |
| $32.27 | $44.83 | $67.39 | +133% | Bullish | |
| $36.90 | $52.43 | $80.74 | +172% | Bullish | |
| $36.65 | $53.19 | $83.70 | +176% | Bullish | |
| $39.35 | $58.26 | $93.50 | +202% | Bullish | |
| $41.08 | $61.98 | $101.26 | +221% | Bullish | |
| $46.52 | $71.49 | $118.75 | +271% | Bullish | |
| $71.44 | $119.32 | $212.39 | +519% | Bullish | |
| $144.00 | $278.55 | $547.88 | +13.4x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $9.13 | $19.28 | $22.77 | +0.00% |
| September 2026 | $15.36 | $18.26 | $22.38 | -5.31% |
| October 2026 | $15.69 | $18.81 | $23.35 | +3.02% |
| November 2026 | $16.16 | $19.50 | $24.45 | +3.66% |
| December 2026 | $15.98 | $19.40 | $24.54 | -0.51% |
Click any year to see its month-by-month ANIK forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ANIK to range from $9.13 to $24.54 through 2026. The $19.28 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The ANIK price prediction for 2027 points to an average of $23.09 (low $18.12, high $31.26) — a potential gain of +20% on today's $19.28. A consolidation phase looks the most probable path here.
In 2028, ANIK is projected to trade between $21.96 and $40.91, averaging $28.94 — a potential gain of +50% from today's $19.28. That is up +25% on the projected 2027 average. Momentum favours further upside here.
Anika Therapeutics, Inc.'s 2029 outlook centres on $33.90, within a $25.02 to $49.56 range. That is up +17% on the projected 2028 average. That marks a +76% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, ANIK could reach as high as $67.39, with a base case around $44.83 and support toward $32.27 — roughly +133% from $19.28. Momentum favours further upside here.
Expect ANIK to range from $36.90 to $80.74 through 2031. The $52.43 average target implies a +172% move from current prices. That is up +17% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The ANIK price prediction for 2032 points to an average of $53.19 (low $36.65, high $83.70) — a potential gain of +176% on today's $19.28. Momentum favours further upside here.
In 2033, ANIK is projected to trade between $39.35 and $93.50, averaging $58.26 — a potential gain of +202% from today's $19.28. That is up +10% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Anika Therapeutics, Inc.'s 2034 outlook centres on $61.98, within a $41.08 to $101.26 range. That is up +6% on the projected 2033 average. That marks a +221% change versus current levels. Momentum favours further upside here.
By 2035, ANIK could reach as high as $118.75, with a base case around $71.49 and support toward $46.52 — roughly +271% from $19.28. Buyers look set to stay in control over this stretch.
Expect ANIK to range from $71.44 to $212.39 through 2040. The $119.32 average target implies a +519% move from current prices. That is up +67% on the projected 2035 average. Momentum favours further upside here.
The ANIK price prediction for 2050 points to an average of $278.55 (low $144.00, high $547.88) — a potential gain of +13.4x on today's $19.28. Buyers look set to stay in control over this stretch.
Investing $1,000 in ANIK today (≈ 51.86722 ANIK) could be worth
$14,447.64
+$13,447.64 (+1345%) by 2050 · US Dollar
Based on the average projected ANIK price of $278.55 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ANIKwould be worth at today's price.
$1,000 invested in ANIK on Jul 31, 2025 (≈ 121.065372 ANIK) would be worth
$2,334.14
+$1,334.14 (+133.4%) today · 2.33× · US Dollar
Based on a ANIK entry price of $8.26 vs. today's $19.28.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $14.95 | $1,289.63 | +29.0% |
| 1 month ago | $15.18 | $1,270.09 | +27.0% |
| 3 months ago | $14.85 | $1,298.32 | +29.8% |
| 6 months ago | $9.63 | $2,002.08 | +100.2% |
| 1 year ago | $8.26 | $2,334.14 | +133.4% |
| All time (5.0y) ago | $40.86 | $471.86 | -52.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ANIK forecast.
Our base-case forecast reaches $39.00 around 2030.
Implied market cap at $39.00: $521.94M
The multi-year forecast points to a bullish trajectory across the horizon. 2026 shows an avg of $18.07 with a min of $9.13 and a max of $22.92 (ROI 0; sentiment NEUTRAL). By 2027 the avg is $21.54 (min $17.02, max $28.93; ROI 19.2; sentiment NEUTRAL), and by 2028 the avg rises to $26.57 (min $20.34, max $37.17; ROI 47; sentiment BULLISH).
The path continues to 2029 with an avg of $30.80 (min $22.97, max $44.47; ROI 70.4; sentiment BULLISH) and 2030 with an avg of $40.53 (min $29.54, max $60.09; ROI 124.3; sentiment BULLISH). Further out, 2035 shows an avg of $63.42 (min $42.10, max $103.45; ROI 251; sentiment BULLISH), 2040 an avg of $104.91 (min $64.52, max $182.86; ROI 480.6; sentiment BULLISH), and 2050 an avg of $240.00 (min $129.15, max $460.47; ROI 1228.2; sentiment BULLISH). These figures illustrate a long-run upswing with substantial upside but remain estimates, not guarantees, and actual results will vary with market conditions and other risks.
Tap a question to reveal the answer.
The 2030 forecast shows an avg of $40.53 with a min of $29.54 and a max of $60.09; ROI 124.3; sentiment BULLISH. These are estimates and not guarantees of future performance.
The forecast depicts a bullish trajectory from 2027 onward with rising averages (e.g., $21.54 in 2027, $26.57 in 2028, $30.80 in 2029, $40.53 in 2030) and notable long-term upside (2035 $63.42, 2040 $104.91, 2050 $240.00; ROI up to 1228.2). These are projections and not guarantees, and investing involves risk.
According to the forecast, the 2030 max is $60.09, which would indicate a potential reach of around that level if the forecast proves accurate.
The 2050 forecast shows an avg of $240.00 with a min of $129.15 and a max of $460.47; ROI 1228.2; sentiment BULLISH. These are estimates, not guarantees.
Anika Therapeutics, Inc. Community Discussion
0Share your Anika Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.